2026-09-25T03:11:05Zhttps://cora.ucc.ie/server/oai/request

oai:cora.ucc.ie:10468/26262023-04-04T07:00:20Zcom_10468_901com_10468_3com_10468_438com_10468_386com_10468_4com_10468_1com_10468_848col_10468_902col_10468_439col_10468_387col_10468_140col_10468_1186

Not applicable No embargo required No No embargo required No Embargo Required Molloy, D. William Sammon, David Gao, Yang 2016-05-25T16:39:10Z 2016-05-25T16:39:10Z 2014 2014 Alzheimer’s Disease and other dementias are one of the most challenging illnesses confronting countries with ageing populations. Treatment options for dementia are limited, and the costs are significant. There is a growing need to develop new treatments for dementia, especially for the elderly. There is also growing evidence that centrally acting angiotensin converting enzyme (ACE) inhibitors, which cross the blood-brain barrier, are associated with a reduced rate of cognitive and functional decline in dementia, especially in Alzheimer’s disease (AD). The aim of this research is to investigate the effects of centrally acting ACE inhibitors (CACE-Is) on the rate of cognitive and functional decline in dementia, using a three phased KDD process. KDD, as a scientific way to process and analysis clinical data, is used to find useful insights from a variety of clinical databases. The data used are from three clinic databases: Geriatric Assessment Tool (GAT), the Doxycycline and Rifampin for Alzheimer’s Disease (DARAD), and the Qmci validation databases, which were derived from several different geriatric clinics in Canada. This research involves patients diagnosed with AD, vascular or mixed dementia only. Patients were included if baseline and end-point (at least six months apart) Standardised Mini-Mental State Examination (SMMSE), Quick Mild Cognitive Impairment (Qmci) or Activities Daily Living (ADL) scores were available. Basically, the rates of change are compared between patients taking CACE-Is, and those not currently treated with CACE-Is. The results suggest that there is a statistically significant difference in the rate of decline in cognitive and functional scores between CACE-I and NoCACE-I patients. This research also validates that the Qmci, a new short assessment test, has potential to replace the current popular screening tests for cognition in the clinic and clinical trials. Not peer reviewed Accepted Version application/pdf Gao, Y. 2014. The effects of centrally acting ACE inhibitors on the rate of cognitive and functional decline in dementia: a KDD approach. PhD Thesis, University College Cork. 280 https://hdl.handle.net/10468/2626 en University College Cork © 2014, Yang Gao. http://creativecommons.org/licenses/by-nc-nd/3.0/ Dementia Alzheimer’s disease Centrally acting angiotensin converting enzyme inhibitors Knowledge discovery Data analysis Qmci true The effects of centrally acting ACE inhibitors on the rate of cognitive and functional decline in dementia: a KDD approach Doctoral thesis Doctoral PHD (Business Information Systems) w.molloy@ucc.ieinfo:eu-repo/semantics/openAccess